GSK's long-acting asthma drug halved attacks in phase 3, backing up blockbuster hopes

GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the Big Pharma’s push toward approval despite falling short on some secondary endpoints.